Holen Sie sich die Stockscreener-App
106.64
1.34%
-1.62
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance
Will Incyte Corporation stock see PE expansionJuly 2025 Update & Verified Momentum Watchlists - newser.com
Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada
Incyte stock hits 52-week high at 108.81 USD - Investing.com
Peering Into Incyte Corp's Recent Short Interest - Benzinga
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MyChesCo
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy - MyChesCo
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance
Incyte at Guggenheim Conference: Strategic Focus on Innovation - Investing.com
Can Incyte Corporation stock hit record highs again2025 Performance Recap & Real-Time Volume Analysis - newser.com
Published on: 2025-11-10 05:29:16 - newser.com
Key metrics from Incyte Corporation’s quarterly dataStop Loss & Long-Term Safe Investment Ideas - newser.com
Forecasting Incyte Corporation price range with options data2025 Analyst Calls & AI Enhanced Trade Execution Alerts - newser.com
Can Incyte Corporation stock deliver sustainable ROEMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MyChesCo
Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments - MyChesCo
Incyte to Highlight Innovation at Major Global Healthcare Conferences in November - MyChesCo
Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline Realignment - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock outperform Dow Jones indexBull Run & Weekly High Momentum Picks - newser.com
How Incyte Corporation stock responds to policy changesWeekly Trend Report & Smart Money Movement Alerts - newser.com
Incyte EVP Denton sells $60,613 in stock By Investing.com - Investing.com South Africa
Incyte EVP Denton sells $60,613 in stock - Investing.com India
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Is It Time to Reevaluate Incyte After Strong Pipeline Update and 52% Price Surge? - Yahoo Finance
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema - The Joplin Globe
Leading vs lagging indicators on Incyte Corporation performanceJuly 2025 Summary & Real-Time Volume Triggers - newser.com
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Can Incyte Corporation (ICY) stock attract analyst upgradesShort Setup & Smart Money Movement Alerts - newser.com
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Incyte stock hits 52-week high at 103.93 USD - Investing.com
Prelude Therapeutics (PRLD) Is Up 14.3% After Incyte Option Deal and Pipeline Shift Has the Bull Case Changed? - Yahoo Finance
Incyte Unveils Game-Changing mCALR Trials – What It Means for Blood Cancer Treatment! - Smartkarma
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program By Investing.com - Investing.com South Africa
Incyte (INCY) Receives Raised Price Target from Piper Sandler | - GuruFocus
Incyte (NASDAQ:INCY) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Incyte aboard, SMARCA2 shift by Prelude enshrouds Foghorn - BioWorld MedTech
Prelude Therapeutics Signs Option Agreement with Incyte - TipRanks
Incyte (NASDAQ:INCY) Upgraded by Guggenheim to Buy Rating - MarketBeat
Incyte (INCY) Secures Option for JAK2V617F Program in $910M Deal - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program - Investing.com
Incyte (INCY) Secures Exclusive Option on JAK2V617F Program - GuruFocus
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com
Prelude Therapeutics Announces Strategic Updates: Prioritizes JAK2V617F and KAT6A Programs, Pauses SMARCA2 Development and Secures $60 Million from Incyte Option Agreement - Quiver Quantitative
Hussman Strategic Advisors Inc. Boosts Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage - Insider Monkey
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - Yahoo Finance
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call - Barchart.com
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corporation (INCY) Stock forecasts - Yahoo! Finance UK
Is Incyte Corporation (ICY) stock dividend growth reliableJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Incyte Corp. Stock Climbs 8.7%, Outperforms Peers - 富途牛牛
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte (INCY) Upgraded to Buy by Guggenheim, Price Target Set at $125 | INCY Stock News - GuruFocus
Incyte stock jumps on promising cancer data - Investing.com
Is It Too Late to Ride INCY’s Upsurge? - timothysykes.com
Is Incyte Soaring or Sinking? - StocksToTrade
Incyte (INCY) Shares Rise Following Promising Myelofibrosis Data - GuruFocus
0.38%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):